This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
December 04, 2017
Nordic Nanovector to Present at Carnegie Nordic Healthcare day
December 01, 2017
Nexstim Plc Appoints Steve Beller as Vice President and General Manager, North America
November 30, 2017
Targovax ASA: New member of the board of directors
November 30, 2017
Orexo publishes prospectus and applies for listing of bonds on Nasdaq Stockholm
November 28, 2017
Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting
November 23, 2017
Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017
November 22, 2017
First patients enter TARGET study, recently initiated by Cerenis Therapeutics to evaluate HDL nanoparticles in patients with esophageal cancer
November 22, 2017
Nordic Nanovector Capital Markets Day 2017
November 22, 2017
Nordic Nanovector ASA – Results for the Third Quarter 2017
November 20, 2017
Zubsolv® receives authorization for treatment of opioid dependence in Europe